Protagonist Therapeutics (PTGX) Tops Q1 EPS by 54c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/30/2026
- Wall Street ends lower as Alphabet revenue miss revives AI capex jitters
- Alphabet shares tumble 10% as earnings miss overshadows cloud boom
- Microsoft rises premarket as cloud strength drives earnings beat
- Caterpillar shares slump 10% despite earnings beat amid rapid AI buildout
- DoorDash to acquire Instacart in $17 billion deal
Tweet
Share
E-mailGet Alerts PTGX Hot Sheet
Join SI Premium – FREE
Protagonist Therapeutics (NASDAQ: PTGX) reported Q1 EPS of $0.05, $0.54 better than the analyst estimate of ($0.49). Revenue for the quarter came in at $56.37 million versus the consensus estimate of $12.2 million.
For earnings history and earnings-related data on Protagonist Therapeutics (PTGX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades First Busey (BUSE) to Market Perform
- First Northern Community Bancorp (FNRN) Tops Q3 EPS by 38c
- Silvercrest Asset Management (SAMG) Tops Q3 EPS by 5c
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
